(Q36409125)

14 August 2017

1 reference

title

Definition of at-risk patients: baseline variables (English)

1 reference

14 August 2017

Claus G Roehrborn

1

1 reference

14 August 2017

publication date

1 April 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

97 Suppl 2

1 reference

14 August 2017

page(s)

7-11; discussion 21-2

1 reference

Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06098.X

Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06098.X

Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06098.X

The urologist view of BPH progression: results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06098.X

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06098.X

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06098.X

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06098.X

Distribution of post-void residual urine volume in randomly selected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06098.X

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06098.X

Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06098.X

Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06098.X

10.1111/J.1464-410X.2006.06098.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference